116 related articles for article (PubMed ID: 38423671)
1. Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.
Inomata M; Minatoyama S; Takata N; Hayashi K; Hirai T; Seto Z; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Matsuyama K; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2024 Mar; 44(3):1241-1245. PubMed ID: 38423671
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Platinum-combination chemotherapy with or without immune-checkpoint inhibitor in patients with postoperative recurrent non-small cell lung cancer previously treated with adjuvant platinum-doublet chemotherapy: A multicenter retrospective study.
Hisakane K; Tozuka T; Takahashi S; Taniuchi N; Nishijima N; Atsumi K; Okano T; Seike M; Hirose T
Thorac Cancer; 2023 Jul; 14(21):2069-2076. PubMed ID: 37290434
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Shao T; Zhao M; Liang L; Tang W
Front Immunol; 2022; 13():948597. PubMed ID: 36389713
[TBL] [Abstract][Full Text] [Related]
5. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
Perez BA; Kim S; Wang M; Karimi AM; Powell C; Li J; Dilling TJ; Chiappori A; Latifi K; Rose T; Lannon A; MacMillan G; Saller J; Grass GD; Rosenberg S; Gray J; Haura E; Creelan B; Tanvetyanon T; Saltos A; Shafique M; Boyle TA; Schell MJ; Conejo-Garcia JR; Antonia SJ
Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):425-435. PubMed ID: 33002543
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancer.
Xu J; Liu X; Yang S; Shi Y
J Cancer Res Ther; 2022 Sep; 18(5):1425-1431. PubMed ID: 36204892
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
8. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?
Zhao Y; Mei T; Na F; Tian X; Ao R; Long X; Luo Q; Duan P; Zhu J; Wang Y; Huang M; Liu Y; Gong Y
Invest New Drugs; 2024 Apr; 42(2):196-206. PubMed ID: 38386170
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
Park S; Keam B; Kim SH; Kim KH; Kim YJ; Kim JS; Kim TM; Lee SH; Kim DW; Lee JS; Heo DS
Cancer Res Treat; 2015 Oct; 47(4):630-7. PubMed ID: 25687850
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Taniguchi Y; Shimokawa T; Takiguchi Y; Misumi T; Nakamura Y; Kawashima Y; Furuya N; Shiraishi Y; Harada T; Tanaka H; Miura S; Uchiyama A; Nakahara Y; Tokito T; Naoki K; Bessho A; Goto Y; Seike M; Okamoto H
Clin Cancer Res; 2022 Oct; 28(20):4402-4409. PubMed ID: 35980349
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
14. Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy.
Hayashi H; Nishio M; Takahashi M; Tsuchiya H; Kasahara-Kiritani M
Adv Ther; 2023 Oct; 40(10):4545-4560. PubMed ID: 37572265
[TBL] [Abstract][Full Text] [Related]
15. Could S-1-based non-platinum doublet chemotherapy be a new option as a second-line treatment for advanced non-small cell lung cancer patients? A multicenter retrospective study.
Wang X; Wang T; Chu Y; Liu J; Yi C; Yu X; Wang Y; Zheng T; Cao F; Qu L; Yu B; Liu H; Ding F; Wang S; Wang X; Hao J; Wang X
Front Oncol; 2023; 13():1089234. PubMed ID: 37007066
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
Li Y; Liang X; Li H; Chen X
Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study.
Matsumoto K; Shiroyama T; Tamiya M; Minami T; Kinehara Y; Tamiya A; Suga Y; Kuge T; Mori M; Suzuki H; Tobita S; Ueno K; Namba Y; Tetsumoto S; Niki T; Morimura O; Osa A; Nishino K; Nagatomo I; Takeda Y; Kijima T; Kumanogoh A
Cancer Immunol Immunother; 2024 Jan; 73(1):4. PubMed ID: 38175294
[TBL] [Abstract][Full Text] [Related]
19. Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis.
Molife C; Brnabic A; Stefaniak VJ; Belger MA; Gruver K; Chen JV; Souri S; Blumenschein GR
Immunotherapy; 2023 Mar; 15(4):293-309. PubMed ID: 36748406
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
